Pisa syndrome after rasagiline therapy in a patient with Parkinson’s disease

Valentino, Francesca; Cosentino, Giuseppe; Fierro, Brigida; Realmuto, Sabrina; Mastrilli, Sergio; Savettieri, Giovanni; D’Amelio, Marco

doi:10.1007/s10072-015-2374-z

Cited by 6 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We wish to highlight that neither selegiline nor rasagiline improves LIDs through a direct mechanism, but they allow to reduce the daily dose od L-DOPA without a major impairment of motor control. Reversible Pisa syndrome, a postural deformity characterized by lateral trunk flexion, has been occasionally associated with rasagiline treatment in a patient affected by PD [63,64]. Whether this rare complication is due to inhibition of DA metabolism or other mechanisms remains to be established.…”

Section: Effects Of Mao B Inhibitors On Motor Symptoms Associated With Pd and Their Impact On Motor Complications Of L-dopa Treatmentmentioning

confidence: 99%

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside

Alborghetti

Nicoletti

2019

View full text Add to dashboard Cite

Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are used for the treatment of Parkinson's disease (PD). All three drugs improve motor signs of PD, and are effective in reducing motor fluctuations in patients undergoing long-term L-DOPA treatment. Their effect of MAOB inhibitors on non-motor symptoms is not uniform and may not be class-related. Selegiline and rasagiline are irreversible inhibitors forming a covalent bond within the active site of MAOB . In contrast, safinamide is a reversible MAOB inhibitor, and also inhibits voltage-sensitive sodium channels and glutamate release Safinamide is the prototype of a new generation of multi-active MAOB inhibitors, which includes the antiepileptic drug, zonisamide. Inhibition of MAOB-mediated dopamine metabolism largely accounts for the antiparkinsonian effect of the three drugs. Dopamine metabolism by MAOB generates reactive oxygen species, which contribute to nigro-striatal degeneration. Among all antiparkinsonian agents, MAOB inhibitors are those with the greatest neuroprotective potential because of inhibition of dopamine metabolism, induction of neurotrophic factors, and, in the case of safinamide, inhibition of glutamate release. The recent development of new experimental animal models that more closely mimic the progressive neurodegeneration associated with PD will allow to test the hypothesis that MAOB inhibitors may slow the progression of PD.

show abstract

Section: Effects Of Mao B Inhibitors On Motor Symptoms Associated With Pd and Their Impact On Motor Complications Of L-dopa Treatmentmentioning

confidence: 99%

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside

Alborghetti

Nicoletti

2019

View full text Add to dashboard Cite

show abstract

Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management

et al. 2016

View full text Add to dashboard Cite

Pisa syndrome was first described in 1972 in patients treated with neuroleptics. Since 2003, when it was first reported in patients with Parkinson's disease (PD), Pisa syndrome has progressively drawn the attention of clinicians and researchers. Although emerging evidence has partially clarified its prevalence and pathophysiology, the current debate revolves around diagnostic criteria and assessment and the effectiveness of pharmacological, surgical, and rehabilitative approaches. Contrary to initial thought, Pisa syndrome is common among PD patients, with an estimated prevalence of 8.8% according to a large survey. Furthermore, it is associated with the following specific patient features: more severe motor phenotype, ongoing combined pharmacological treatment with levodopa and dopamine agonists, gait disorders, and such comorbidities as osteoporosis and arthrosis. The present literature on treatment outcomes is scant, and the uneven effectiveness of specific treatments has produced conflicting results. This might be because of the limited knowledge of Pisa syndrome pathophysiology and its variable clinical presentation, which further complicates designing randomized clinical trials on this condition. However, because some forms of Pisa syndrome are potentially reversible, there is growing consensus on the importance of its early recognition and the importance of pharmacological adjustment and rehabilitation. © 2016 International Parkinson and Movement Disorder Society.

show abstract

Definition and Classification of Parkinsonian Drugs

Mizuno

2022

NeuroPsychopharmacotherapy

View full text Add to dashboard Cite

Pisa syndrome after rasagiline therapy in a patient with Parkinson’s disease

Cited by 6 publications

References 3 publications

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside

Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management

Definition and Classification of Parkinsonian Drugs

Contact Info

Product

Resources

About